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Abstract Elafin is a low molecular weight antiproteinase
believed to be important in the regulation of elastase mediated
tissue damage. The expression of elafin is known to be regulated
by proinflammatory cytokines such as interleukin-1L and tumour
necrosis factor but little was known regarding the effect of
human neutrophil elastase (HNE). Employing a chloramphenicol
acetyltransferase reporter construct of the human elafin gene,
reverse transcription PCR from total cellular RNA and ELISA
techniques, we have examined the effect of human neutrophil
elastase on the transcription and secretion of human elafin in the
pulmonary epithelial A549 cell line. Stimulation with HNE at
concentrations of 10310 and 10311 M resulted in a significant
upregulation of elafin promoter activity. Similarly, transcription
of the endogenous human elafin gene was upregulated with HNE
concentrations ranging from 10310 to 10312 M. In addition, we
demonstrate that stimulation with HNE at concentrations
ranging from 1039 and 10312 M resulted in a significant
reduction in the secreted elafin protein as measured in the cell
supernatant. These results provide further evidence for a role of
elafin in the regulation of HNE driven proteolysis of the
extracellular matrix.
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1. Introduction
The excessive or unregulated release of proteolytic enzymes
from in£ammatory cells in the lung has been implicated in the
pathogenesis of acute and chronic in£ammatory lung diseases
[1,2]. Amongst many potentially injurious agents, the serine
protease, human neutrophil elastase (HNE), has emerged as a
key e¡ector of lung injury and its regulation is likely to be of
critical importance in the maintenance of lung defence. The
lung is known to contain at least three antiproteinases with
activity against HNE: K-1 antiproteinase (A1Pi), secretory
leukocyte protease inhibitor (SLPI) and elastase speci¢c inhib-
itor (ESI), also called ela¢n or SKALP (skin derived antileu-
koprotease) [3,4].
Ela¢n was simultaneously described in psoriatic skin and
bronchial secretions [5^8] but is present in many tissues [9]. In
common with SLPI, ela¢n inhibits HNE, but in addition, is
also a potent inhibitor of a second neutrophil derived pro-
tease: proteinase-3 (PR-3) [5,6]. The gene encoding ela¢n is
found on chromosome 20 [10] and has been sequenced [11,12].
The 5P £anking region has the characteristics of a gene whose
regulation is governed at a tissue level. Consensus sequences
may be found for ‘TATA’ and ‘CAAT’ boxes together with
numerous putative binding sites for transcription factors
known to regulate the transcriptional activity of tissue regu-
lated genes [13]. Furthermore the di¡erential expression of
ela¢n in normal mammary cells and breast carcinoma cells
appears to be regulated at a transcriptional level and mediated
through the transcription factor activating protein-1 (AP-1)
[14].
Although the expression of ela¢n has been shown to be
regulated at the transcriptional level by interleukin L-1 (ILL-
1) and tumour necrosis factor (TNF) [15,16], the e¡ect of
HNE on the expression and secretion of ela¢n has not been
described. In this study we used a reporter construct of the
human ela¢n gene promoter, reverse transcription polymerase
chain reaction (RT-PCR) and an enzyme linked immunosor-
bent assay (ELISA) to investigate the potential of HNE to
regulate the secretion of ela¢n.
2. Materials and methods
2.1. Cell lines and media
The pulmonary epithelial A549 cell line derived from a human lung
bronchioloalveolar carcinoma and representative of the pulmonary
type II pneumocyte was employed in this study [17]. Cells were main-
tained in Eagle’s minimum essential medium (MEM) supplemented
with 10% foetal calf serum, 1% L-glutamine and 1% penicillin/strepto-
mycin at 37‡C in a 5% CO2 atmosphere.
2.2. pCAT reporter system
Using placental genomic DNA as a template [11], PCR was em-
ployed to amplify a segment of the ela¢n human gene promoter from
3505 bp to +28 bp [13]. Primers were obtained from MWG Biotech
(Ebersberg, Germany) and primer sequences were as follows: +28 (5P-
CAT ACC AAT CTT TAT GCA GTC CAG-3P) and 3505 (5P-CGT
CTC TGA AAC AGC AAA GTG CAA-3P). The PCR fragment was
cloned, using standard techniques, into the PGEM-T cloning vector
(Promega, Southampton, UK). A PstI and SphI restriction fragment
was subcloned into the corresponding sites in the pBasic CAT vector
(Promega, UK), 5P of the CAT reporter gene. Sense and antisense
strands of the DNA product were sequenced by Appligene Oncor
(Illkirch, France) and were identical to those previously published
except for the presence of an additional thymidine residue between
positions 36 and 41. This construct was denoted 505-ela¢n.
2.3. Cell transfection
Pulmonary A549 cells were transfected using the cationic liposome
TFX-20 (Promega, UK). Cells were grown to approximately 80%
con£uence in 60 mm cell culture dishes (Corning Costar, High Wy-
combe, UK). The medium was removed and cells washed with sterile
phosphate bu¡ered saline (PBS), pH 7.4 (Sigma, Poole, UK) and 10 Wg
of 505-ela¢n DNA was combined in a 1:2 charge ratio with TFX-20
in serum free MEM. 5 Wg of the L-galactosidase expression plasmid
pPSV-GAL (Promega, UK) was included as an internal transfection
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control. pCAT basic (lacking a promoter) and pCAT control (in
which the CAT gene is under the control of the SV40 promoter and
enhancer sequences) were used as negative and positive controls re-
spectively. Cells were transferred to a 37‡C incubator with a 5% CO2
atmosphere for 1 h following which any excess transfection medium
was removed, the cells washed with sterile PBS and HNE applied as
described below.
2.4. Cell stimulation and CAT ELISA
HNE was provided by Elastin Products (Owensville, MO, USA)
and diluted in serum free MEM. Cells transfected with pCAT con-
structs (see above) were stimulated with HNE, applied in concentra-
tions ranging from 1039 to 10312 M and serum free medium was
harvested after 48 h. The protein content of the lysate was determined
using a BCA reagent (Pierce, Rockford, IL, USA) and 100 Wg protein
added to each well of the CAT ELISA (Boehringer Mannheim,
Lewes, East Sussex, UK). A further aliquot was analysed for expres-
sion of L-galactosidase (Promega, UK). Cell viability was con¢rmed
by trypan blue exclusion on A549 cells treated as above, prior to the
cell lysis step.
2.5. Reverse-transcription PCR (RT-PCR)
To assess expression of ela¢n mRNA in A549 cells following HNE
stimulation, total cellular RNA was isolated using the SV Total RNA
isolation system (Promega, UK). The purity and yield of the RNA
were determined spectrophotometrically by measuring the absorbance
of an aliquot at 260 and 280 nm. RNA integrity was checked by
electrophoresis on a 1.2% agarose gel. The resulting RNA was stored
at 380‡C until RT-PCR was performed. 1 Wg of total cellular RNA
from A549 cells was reverse transcribed using the Access RT-PCR
system (Promega, UK) prior to performing PCR to amplify the
cDNA of ela¢n and the housekeeping gene glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH). As the number of PCR cycles re-
quired to detect ela¢n cDNA (30 cycles) was beyond the linear range
for GAPDH (25 cycles), aliquots were ampli¢ed in a separate reaction
tube. All reactions were carried out in duplicate. For ela¢n RNA
ampli¢cation, a reaction tube consisting of AMV reverse transcriptase
(0.1 U/Wl), AMV/T£ 5U reaction bu¡er (1U), dNTP mix containing
0.2 mM of each nucleotide, 2.5 mM MgSO4, T£ DNA polymerase
(0.1 U/Wl) and ela¢n primers 5P-GCA GCT TCT TGA TCG TGG
TG-3P (downstream) and 5P-GCC GTG GGC ATC CTG AAT GGG-
3P (upstream) to a ¢nal concentration of 1 WM each. Reaction tubes
were made up to a ¢nal volume with 50 Wl of nuclease free water.
Ela¢n primers were chosen to span an intron to facilitate detection of
DNA contamination. After completion of reverse transcription for
48‡C for 45 min ela¢n cDNA was generated after 30 cycles of PCR
(94‡C for 1 min, 55‡C for 1 min and 72‡C for 1 min). The expected
product was 480 bp in length. RT-PCR for GAPDH was performed
in an identical manner using the downstream primer 5P-TCT AGA
CGG CAG GTC AGG TCC ACC-3P and the upstream primer 5P-
CCA CCC ATG GCA AAT TCC ATG GCA-3P. The expected prod-
uct was 600 bp in length. Ampli¢cation products were then analysed
on 1.2% agarose gel followed by densitometry (GelPlate, UVP, Cam-
bridge, UK). The intensity of the ela¢n cDNA band was normalised
to the intensity of the constitutive GAPDH cDNA product.
2.6. Ela¢n ELISA
Supernatants from unstimulated and HNE stimulated A549 cells
were assayed for ela¢n protein content by ELISA. We used a mod-
i¢cation of our original assay [15]. Brie£y, 96 well plates (Linbro,
Flow Labs, McLean, VA, USA) were coated with a 1 in 500 dilution
of anti-ela¢n IgG in carbonate bu¡er, pH 9.6 overnight at 4‡C. After
blocking, samples and standards (diluted in PBS-gelatin) were applied
for 2 h at room temperature followed by a further 2 h incubation with
biotinylated anti-ela¢n IgG at 2 mg/ml. After addition of streptavidin-
horseradish peroxidase (Sigma Chemical Co., St. Louis, MO, USA)
for 2 h at room temperature, plates were washed and 100 Wl of chro-
mogenic substrate (2,2P-azino-bis-3-ethyl benz-thiazoline-6-sulphonic
acid; Sigma Chemical Co., St. Louis, MO, USA) containing 0.001%
H2O2 was applied to each well and absorbance was read at 490 nm
with a microplate reader (Dynatech, Guernsey, UK).
2.7. Statistics
Results are expressed as mean þ S.E.M. and represent the mean of
three experiments. Results were analysed using ANOVA following
rank transformation of data. P6 0.05 was accepted as signi¢cant.
3. Results
3.1. E¡ect of HNE on expression of the ela¢n promoter
(505-ela¢n construct)
Fig. 1 demonstrates the e¡ect of HNE treatment on the
CAT activity of the 505-ela¢n construct following transfection
into A549 cells. Results are expressed as a percentage of the
basal CAT activity derived from the same construct in the
absence of HNE stimulation (arbitrarily assigned the value
of 100%). HNE at a concentration of 1039 M increased
CAT activity to 109 þ 11%, 10310 M to 147 þ 19%, 10311 M
to 131 þ 9% and 10312 M to 113 þ 7% demonstrating a signi¢-
cant upregulation of the ela¢n promoter stimulation with
Fig. 1. Ela¢n promoter activity after HNE stimulation. A549 cells
were co-transfected with the 505-ela¢n and L-galactosidase con-
structs. Following transfection excess medium was removed and
cells were incubated in serum free medium containing HNE in the
above concentrations for a 48 h period. Cells were then lysed and
CAT activity determined relative to the expression of L-galactosid-
ase. Asterisks indicate statistical signi¢cance (n = 3) from basal con-
ditions (cells with no HNE stimulation).
Fig. 2. Ela¢n mRNA stimulation with HNE in A549 cells. Top:
ela¢n mRNA upregulation as assessed by RT-PCR. Basal: cells
with no HNE stimulation. Bottom: GAPDH expression as assessed
by RT-PCR; M: molecular weight markers (bp).
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10310 and 10311 M HNE (P6 0.05). Cell viability as assessed
by trypan blue demonstrated no signi¢cant di¡erence between
di¡erent treatments.
3.2. E¡ect of HNE on expression of ela¢n mRNA
The e¡ect of HNE on steady-state ela¢n mRNA levels in
A549 cells, relative to the expression of GAPDH mRNA, is
shown in Fig. 2 (a representative experiment) and in Fig. 3
(quanti¢cation from three di¡erent experiments). As above,
the amount of ela¢n mRNA levels in cells receiving medium
without HNE was arbitrarily assigned a value of 100%. Stim-
ulation with HNE at a concentration of 1039 M increased
expression to 184.3 þ 8.3%, 10310 M to 663 þ 186%, 10311 M
to 470 þ 101% and 10312 M to 301 þ 42%. The observed up-
regulation was signi¢cant for concentrations between 10310
and 10312 M (P6 0.05) but did not attain signi¢cance for
1039 M. Cell viability assessed by trypan blue exclusion dem-
onstrated no signi¢cant di¡erence between di¡erent treat-
ments.
3.3. E¡ect of HNE on secretion of the ela¢n protein
The e¡ect of HNE on the secretion of ela¢n protein from
A549 cells is shown in Fig. 4. As above, the level of ela¢n
protein in the supernatant harvested from the untreated cells
was assigned a value of 100%. Stimulation with HNE resulted
in a decrease in ela¢n supernatant content as follows: 1039 M
decreased secretion to 70 þ 5%, 10310 M to 75 þ 12%, 10311 M
to 72 þ 5% and 10312 M to 71 þ 11%. Thus at all concentra-
tions, stimulation of the A549 cells with HNE resulted in a
statistically signi¢cant reduction in the level of secreted ela¢n
in the cell supernatant (P6 0.05).
4. Discussion
The biological function of ela¢n (also called ESI or
SKALP) remains unknown but in view of its speci¢city for
HNE and PR-3, it has been ascribed a role in the proteolytic
regulation of extracellular matrix components [4^8,10]. The
molecular weight of ela¢n is su⁄ciently low to permit access
to the protected neutrophil-substrate microenvironment and
the presence of a repetitive sequence of valine, lysine, glycine
and glutamine residues in the precursor protein (known to
facilitate transglutaminase crosslinking between proteins and
the extracellular matrix) is likely to be important in anchoring
the protein within the interstitial environment of the lung [9^
11].
The expression of ela¢n has been shown to be upregulated
in lung epithelial cells in response to IL-1L and TNF suggest-
ing that it is likely to be a key early component in the lung
defence to in£ammation and injury [15,16]. Further evidence
for the role of ela¢n in the regulation of elastase mediated
tissue damage is provided by this study in which we demon-
strate that the regulation of ela¢n expression in the lung may
be controlled by HNE, one of its main target enzymes. In a
type II pulmonary epithelial cell line, stimulation with HNE
at concentrations of 10310 and 10311 M results in signi¢cant
upregulation of the human ela¢n promoter and transcription
of the ela¢n gene product. The magnitude of upregulation
observed using the promoter construct (maximum 147%,
Fig. 1), although signi¢cant, is less than that observed by
analysis by RT-PCR in which HNE at a concentration of
10310 M resulted in a 6-fold upregulation of the ela¢n
mRNA (Fig. 3). Whilst this may be due to di¡erent sensitiv-
ities between the two experimental techniques it is possible
that this promoter construct does not include other important
regulatory regions necessary for the response elicited by HNE.
Our choice of promoter was based on previous work by
Zhang and colleagues who analysed the e¡ect of serial dele-
tions on the expression of the ela¢n promoter in human mam-
mary cells, ¢nding that maximal expression required the in-
clusion of a region between 3505 and 3386 bp [13]. However,
it is currently not known whether pulmonary cells require the
presence of other regions to provide maximal expression as is
the case for the other antiproteinases found in the lung. In-
deed, the di¡erential expression of SLPI transcripts in the
hepatocellular carcinoma cell line (Hep G2), human uterocer-
Fig. 3. Quanti¢cation of ela¢n mRNA stimulation by HNE. Ela¢n
cDNA band intensities were determined by densitometry and were
normalised with those of GAPDH (see Fig. 2 for a representative
experiment). Asterisks indicate statistical signi¢cance from basal
conditions (n = 3).
Fig. 4. Ela¢n secretion in A549 cells. A549 cells were stimulated
with HNE in serum free medium at the above concentrations for
48 h. Cell supernatants were then harvested and concentration of
ela¢n protein determined by ELISA. Asterisks indicate statistical
signi¢cance (n = 3) from basal conditions (cells with no HNE stimu-
lation).
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vical carcinoma cell line (HeLa) and the pulmonary epithelial
cell lines A549 and HS-24 may be dependent upon the density
of hepatocyte nuclear factor 3/forkhead (HNF-3/fkh) binding
domains [18]. Additionally, it may favour the existence of
other enhancer regions not included in this construct. The
regulation of A1Pi in response to IL-6 is known to be in£u-
enced by the inclusion of an Oct1 site in the 3P enhancer
region which co-operates with the NF-IL-6 site in the 5P en-
hancer through which IL-6 classically mediates its e¡ect [19].
Alternatively, HNE induced upregulation of steady-state ela-
¢n mRNA levels detected by RT-PCR could re£ect increased
mRNA stability, independent of promoter activity. Indeed,
PMA induced SLPI mRNA transcripts have been shown to
be more stable in the pulmonary epithelial HS-24 cell line
than in the HeLa cell line [20].
In both the ela¢n promoter (Fig. 1) and the RT-PCR anal-
ysis (Figs. 2 and 3), we found that a higher concentration of
HNE (1039 M) only produced minimal upregulation of ela¢n.
To rule out a possible toxic e¡ect we assessed cell viability by
trypan blue exclusion and found no signi¢cant di¡erence be-
tween treatments. Signi¢cantly, similar results have been ob-
served in relation to SLPI by other investigators: Saitoh and
colleagues have reported that whilst HNE at concentrations
between 10310 and 10312 M upregulated the expression of
SLPI mRNA in human airway submucosal gland tissue, high-
er HNE concentrations (1037^1038 M) did not [21]. The ex-
pression of SLPI mRNA has also been shown by us and
others to be induced by HNE but has been demonstrated to
be reduced in epithelium from in£amed pulmonary airway
epithelium [15,22,23]. This observation is worthy of further
studies as the airways of patients with in£ammatory lung
diseases such as cystic ¢brosis (CF) and acute respiratory
distress syndrome demonstrate high levels of unbound HNE
[24,25] which may impair the local expression of small molec-
ular weight inhibitors contributing to an uncontrolled in£am-
matory response. Inhibition of the expression of ela¢n by high
elastase concentrations will also impair protection against PR-
3 which has recently been shown to be present in high levels
within the CF airway and can be correlated with markers of
airway in£ammation and levels of lung function [26]. Interest-
ingly, we found recently in a CF tracheal cell line that HNE
also downregulated the ela¢n promoter activity at higher con-
centrations whereas it upregulated its activity at low concen-
trations [27].
The apparent dissociation between the upregulation of the
transcriptional product and the downregulation of the se-
creted protein is intriguing (Fig. 4). Similar observations
have been made by both our group and others with respect
to SLPI in which HNE stimulation resulted in a signi¢cant
upregulation of SLPI mRNA but an apparent downregulation
of protein secretion [15,28,29]. As our ELISA recognises
HNE-ela¢n complexes within the ranges reported in these ex-
periments, this downregulation cannot be accounted for by an
artefact of our ELISA. One possible explanation could be that
a proportion of the secreted protein remains bound to the cell
surface. It has recently been shown that the HNE mediated
downregulation of SLPI protein in primary bronchial epithe-
lial cells may be prevented by incubating the cells with A1Pi
[29]. HNE treatment may thus sequester inhibitors such as
ela¢n and SLPI on the cell surface which may then be released
when A1Pi becomes available and facilitates the transfer of
HNE to this larger inhibitor [30]. As a further possibility we
may also consider that ela¢n may be synthesised for intra-
cellular use. The expression of ela¢n is known to be subject
to cell cycle regulation, being downregulated during the S
phase, suggesting that it may possess an intracellular protease
target involved in cell cycle regulation [13].
In summary, our data provide the ¢rst demonstration, as
far as we are aware, using three independent techniques, that
the expression and secretion of ela¢n in the human lung is
regulated by HNE. The genesis of serial reporter deletion
constructs should enable the dissection of the key regulatory
regions involved and is the subject of further work by our
group.
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